|
|
cardiabase currently supplies more than 30 international pharmaceutical companies, device manufacturers and biotechnology companies.
|
 |
 |
cardiabase has seen constant growth since its foundation |
|
It is anticipated that over 100 projects will be conducted in 2009, including 12 thorough QT studies.
The proportion of repeat business of cardiabase is significant (between 80% and 90% of the annual volume) while the number of new sponsors keeps on growing.
cardiabase supports a growing number of Phase III multinational trials, thanks to significant efforts spent on setting up the necessary logistics and site support services.
|
|
|
|
Key Advantages
|
Thanks to its know-how in medical logistics, cardiabase has launched a new service for the Central Management of Clinical Dossiers.
This service is used in studies requiring a central data review by Adjudication or Clinical Events Committees.
|
|
|
|
